ÀÓÀçÁØ ¸íÀÇ

Æä°áÇÙ Ä¡·á ±ÇÀ§ÀÚ, ȯÀÚ À§ÇÑ Å¬¸®´Ð ¿î¿µ

ÀÓÀçÁØ ¸íÀÇ

  • ¼Ò ¼Ó
    ¼­¿ï´ëº´¿ø È£Èí±â³»°ú
  • Àü¹®ºÐ¾ß
    °áÇÙ, ´ÙÁ¦³»¼º°áÇÙ, ºñ°áÇÙÇ×»ê±Õ ÆóÁúȯ

ÁÖ¿ä Áø·á ºÐ¾ß´Â Æó°áÇÙ, õ½Ä, Æó·Å µî°ú °°Àº È£Èí±âÁúȯÀÌ´Ù. ¸ÅÁÖ ÇÑ ¹ø¾¿ ¼­¿ï´ëº´¿øÀ» óÀ½ ¹æ¹®Çϴ ȣÈí±âÁúȯ ȯÀÚ¸¦ À§ÇÑ 15ºÐ Áø·á Ŭ¸®´ÐÀ» ¿î¿µÇϸç ȯÀÚµéÀÇ À̾߱⸦ ±Í´ã¾Æµè°í ÀÖ´Ù. ±×µ¿¾È Áúº´¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ÐÈ÷±â À§ÇØ °áÇÙ°ú ºñ°áÇÙÇ×»ê±ÕÁõÀÇ ´Ù¾çÇÑ Ãø¸é¿¡ ´ëÇÑ ¿¬±¸¸¦ ÇØ¿Ô´Ù¸é, ÃÖ±Ù¿¡´Â º¸´Ù ³ªÀº Ä¡·á ¹æ¹ý °³¹ßÀ» À§ÇÑ ÀÓ»ó ½ÃÇè¿¡ ÁÖ·ÂÇϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • Columbia ´ëÇб³ °ø°øº¸°Ç´ëÇпø ȯÀÚÁß½ÉÇü ¿¬±¸ ¼®»ç (2007 ~ 2009 )
  • ¼­¿ï´ëÇб³ Àǰú´ëÇпø ³»°úÇÐ ÀÇÇйڻç
  • ¼­¿ï´ëÇб³ ÀÇÇдëÇпø ³»°úÇÐ ¼®»ç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇлç
  • ¼­¿ï´ëÇб³ ÀÚ¿¬°úÇдëÇÐ ÀÇ¿¹°ú

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼­¿ï´ëÇб³º´¿ø °ø°øºÎ¿øÀå
  • úÞ) ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ³»°úÇб³½Ç ¹× ¼­¿ï´ëº´¿ø ³»°ú ±³¼ö
  • ¹Ì ±¹¸³º¸°Ç¿ø (National Institute of Health) ¿¬±¸¿ø (2001 ~ 2002)

¼ö»ó³»¿ª

Awards List
  • ¼­¿ï´ëµ¿Ã¢È¸ ÇÔÃáÇмú»ó (2015)
  • ¼­¿ï½ÃÀÇ»çȸ À¯ÇѾçÇà À¯ÇÑÀÇÇлó ¿ì¼ö»ó (2014)
  • ¼­¿ï´ëº´¿ø ½ÉÈ£¼· Çмú»ó (2008)
  • ¼­¿ï´ëº´¿ø ÀþÀº ¿¬±¸ÀÚ»ó (2007)
  • ´ëÇÑÀÇÇÐȸ È­ÀÌÀÚÁ¦¾à È­ÀÌÀÚÀÇÇÐ ¿¬±¸»ó (2007)
  • Çѱ¹°úÇбâ¼ú´ÜüÃÑ¿¬ÇÕȸ ¿ì¼ö°úÇбâ¼ú³í¹®»ó (2006)
  • ¼­¿ïÀÇ´ë ³»°úµ¿¹®È¸ ÇÔÃá³»°ú Çмú»ó (2005)

ÇÐȸȰµ¿

Academic activities
  • 2016 ~ ÇöÀç Fleischner Society ȸ¿ø
  • 1997 ~ ÇöÀç´ëÇѰáÇÙ ¹× È£Èí±âÇÐȸ Á¤È¸¿ø
°¡¿îÀ» ¹þÀÚ (ÀÇÇÐ ¼¼»ó°ú ¸¸³ª´Ù)
´ëÇ¥¼­Àû

°¡¿îÀ» ¹þÀÚ (ÀÇÇÐ ¼¼»ó°ú ¸¸³ª´Ù)

  • ÀúÀÚ(±Û)ÀÓÀçÁØ
  • ÃâÆÇ»ç2011³â
  • ¹ßÇàÀÏÀÏÁ¶°¢
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 2°Ç
Á¦ ¸ñ Tuberculosis
ÃâÆÇ»ç Springer ¹ßÇàÀÏ 2004³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense
¹ßÇ¥³âµµ 2017-02 ¹ßÇ¥Áö CLINICAL INFECTIOUS DISEASES
Á¦ ¸ñ Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study
¹ßÇ¥³âµµ 2017-01 ¹ßÇ¥Áö BMC PULMONARY MEDICINE
Á¦ ¸ñ Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial
¹ßÇ¥³âµµ 2017-01 ¹ßÇ¥Áö TRIALS
Á¦ ¸ñ Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist
¹ßÇ¥³âµµ 2017-05 ¹ßÇ¥Áö Annals of the American Thoracic Society
Á¦ ¸ñ Etiquette for medical students' email communication with faculty members: a single-institution study
¹ßÇ¥³âµµ 2016-04 ¹ßÇ¥Áö BMC MEDICAL EDUCATION
Á¦ ¸ñ Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes
¹ßÇ¥³âµµ 2016-03 ¹ßÇ¥Áö Annals of the American Thoracic Society
Á¦ ¸ñ Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis
¹ßÇ¥³âµµ 2016-01 ¹ßÇ¥Áö INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

¼­¿ï´ëº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-5700
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

¼­¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼­ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ­¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.

¼­¿ï´ëº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä